Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis

O. Alfurayh, M. Sobh, Y. Barri, Wajeh Y Qunibi, S. Taher

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

In this work, of 51 patients treated by rHuEpo, 25 were selected for study. The selection criteria were absence of clinically evident causes of anaemia other than end-stage renal failure, such as chronic infection, active systemic disease, bleeding sites, and vitamin B12 or iron deficiencies. Serum aluminium was assessed before dialysis and the presence of aluminium overload was confirmed by a DFO test. rHuEpo was given in a dose of 50 U/kg body- weight after each dialysis session three times weekly and the response to treatment was evaluated monthly for 8 months. Our data showed significant correlation between serum aluminium and the response to rHuEpo. The response was significantly greater in those with lower serum aluminium. We conclude that the aluminium load in chronic haemodialysis patients may have an effect on the response to rHuEpo.

Original languageEnglish (US)
Pages (from-to)939-943
Number of pages5
JournalNephrology Dialysis Transplantation
Volume7
Issue number9
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Keywords

  • Aluminium
  • Erythropoietin
  • Haemodialysis

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis'. Together they form a unique fingerprint.

  • Cite this